MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.humpath.2025.105788

Медицинская библиотека · Human pathology · 2025

Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry.

Korentzelos Dimitrios, Diamantopoulos Leonidas, Mohebnasab Maedeh, Dhir Rajiv, Quiroga-Garza Gabriela M

СтатьяПеревод в очереди

Аннотация

Plasmacytoid urothelial carcinoma (PUC) of the urinary bladder is an aggressive UC subtype characterized by infiltrating cells with plasmacytoid appearance, and somatic CDH1 mutations leading to E-cadherin loss. 32 PUC cases were found in our pathology archives from 2018 to 2024; next-generation sequencing (NGS) was available in 18 cases, and PD-L1 immunohistochemistry in all 32 cases. PD-L1 tumor proportion score (TPS) and combined positive score (CPS) were calculated. Kaplan-Meier method and log-rank test were used for survival analysis. Median patient age was 72.5 years (IQR: 64.3-78.8 years). The cohort consisted predominantly of males (29/32, 91%). 25 patients (78%) underwent radical cystectomy/cystoprostatectomy (RC), while 7 (22%) transurethral resection. Median tumor size was 5.2 cm (IQR of 3.6-8.0 cm). Most RCs (22/25, 88 %) were high-stage (pT3-4). Lymphovascular invasion was identified in 22/25 RCs (88%) and 12/23 RCs (52%) were pN1-2. 17/32 cases (53%) showed a PD-L1 TPS≥1% (6/17 received immune-checkpoint inhibitors - ICIs), while 21/32 (66%) exhibited a CPS≥1% (8/21 received ICIs). Recurrently mutated genes included TP53, TERT, RB1, CREBBP, and ERBB2, among others; our NGS panel does not cover CDH1. Most frequent copy number alterations were RB1, CDKN2A, and CDKN1B losses. Median tumor mutational burden (TMB) was 10.3 mut/Mb (IQR 5.4-15.73 mut/Mb). Median overall survival (OS) was 13.0 months (95% CI 4.2-21.8 months) with some evidence for superior OS among patients with PD-L1 expression. Overall, PUCs frequently exhibit high TMB and/or PD-L1 expression, suggesting a potential for intervention with ICIs. Finally, NGS is recommended to identify actionable alterations, including ERBB2 mutations.

Для цитирования: Korentzelos Dimitrios, Diamantopoulos Leonidas, Mohebnasab Maedeh, Dhir Rajiv, Quiroga-Garza Gabriela M. Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution experience with focus on next-generation sequencing (NGS) and PD-L1 immunohistochemistry.. Human pathology. 2025. DOI: 10.1016/j.humpath.2025.105788.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.